Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?

Biotech Giants' R&D Battle: CRISPR vs. Viking

__timestampCRISPR Therapeutics AGViking Therapeutics, Inc.
Wednesday, January 1, 2014151300022223073
Thursday, January 1, 2015125730006966842
Friday, January 1, 2016422380009000499
Sunday, January 1, 20176980000013741186
Monday, January 1, 201811377300019040000
Tuesday, January 1, 201917936200023559000
Wednesday, January 1, 202026694600031931000
Friday, January 1, 202143863300044981000
Saturday, January 1, 202246164500054234000
Sunday, January 1, 202338733200063806000
Monday, January 1, 2024320653000
Loading chart...

Infusing magic into the data realm

Innovation Race: Viking Therapeutics vs. CRISPR Therapeutics

In the dynamic world of biotechnology, innovation is the lifeblood of progress. Over the past decade, CRISPR Therapeutics AG and Viking Therapeutics, Inc. have been at the forefront of this innovation race. From 2014 to 2023, CRISPR Therapeutics consistently outpaced Viking Therapeutics in research and development (R&D) investments, with an average annual expenditure nearly seven times higher. In 2022, CRISPR Therapeutics peaked with R&D expenses reaching 462 million, while Viking Therapeutics steadily increased its investment, culminating in a 64 million spend in 2023. This trend highlights CRISPR's aggressive pursuit of cutting-edge gene-editing technologies, while Viking focuses on strategic growth in therapeutic development. As the biotech landscape evolves, these investments underscore the companies' commitment to pioneering advancements that could redefine healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025